
 **Annual Henry Ford Cancer Thoracic Multidisciplinary Symposium (2025) | 11/15/2025 7:00 AM The Henry Hotel**

The 3rd Annual Henry Ford Cancer Thoracic Multidisciplinary Symposium is an educational program offering the latest updates in the diagnosis and multidisciplinary management of lung cancer. Through expert lectures, panel discussions, and interactive case sessions, participants will: • Review advances in perioperative immunotherapy, targeted therapy, and surgical approaches for early stage NSCLC • Explore updates in systemic therapy for metastatic NSCLC, including antibody drug conjugates, bispecifics, and novel biomarkers (HER2, MET, ROS1, NRG) • Examine the evolving treatment landscape of small cell lung cancer • Gain insight from a patient advocate on the patient experience in lung cancer care and research. This symposium is designed for oncologists, surgeons, radiation oncologists, pulmonologists, and other members of the thoracic cancer care team seeking practical, evidence based updates to improve patient outcomes.

**Program Goal**

1 Stay up to date with the latest data and clinical practices in the perioperative and metastatic management of NSCLC.

2 Integrate emerging treatments such as bispecific antibodies, antibody-drug conjugates (ADCs), and novel targeted therapies (e.g., HER2, MET, ROS1, NRG) into clinical decision-making.

3 Understand the evolving role of surgery in advanced-stage NSCLC.

4 Recognize the importance of biomarker testing and targeted therapy in early-stage and metastatic NSCLC.

5 Gain insights into current approaches to small cell lung cancer (SCLC), including new standards and evolving paradigms.

6 Appreciate the patient's voice in treatment planning and research, through dedicated advocacy discussions.

7 Enhance their multidisciplinary collaboration by discussing real-world, case-based scenarios with peers across specialties.

**Target Audience** Hematology Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David Bergman, MD | Faculty | Nothing to disclose - 09/09/2025 |
| Andrew Popoff, MD | Faculty | Consulting Fee-Astrazeneca (Relationship has ended)|Consulting Fee-Oxford Performance Materials - 03/26/2025 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 09/02/2025 |
| Alicia Bias, Bachelors | Activity Coordinator | Nothing to disclose - 06/30/2025 |
| Shirish Gadgeel, MD | Faculty | Consulting Fee-Astellas, Boehringer-Ingelheim, Takeda, , Daichii, Lilly, Novartis, Gilead, GSK, Regeneron (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astrazeneca (Relationship has ended)|Consulting Fee-Johnson and Johnson (Relationship has ended)|Advisor-AbbVie (Relationship has ended)|Advisor-Amgen (Relationship has ended)|Advisor-Bayer|Advisor-Genentech (Relationship has ended)|Advisor-Pfizer (Relationship has ended)|Advisor-BMS (Relationship has ended) - 09/29/2025 |
| Avi Cohen, MD | Faculty | Consulting Fee-PulmonX - 09/09/2025 |
| Fawzi Abu Rous, MD | Course Director, Faculty | Advisor-BI (Relationship has ended)|Advisor-DSI (Relationship has ended)|Advisor-MERUS (Relationship has ended)|Advisor-BMS (Relationship has ended)|Advisor-Bayer (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astrazeneca (Relationship has ended)|Advisor-Genentech - 04/28/2025 |
| Denise Brooks, MBA | CME Specialist | Nothing to disclose - 11/27/2024 |
| Linda Albusoul, M.D. | Faculty | Nothing to disclose - 02/04/2025 |
| Radhika Gutta, DO-Fellow | Faculty | Nothing to disclose - 09/25/2025 |
| Bindu R Potugari, MD | Faculty | Consulting Fee-Premier Inc (Relationship has ended)|Consulting Fee-PlatformQ health (Relationship has ended) - 07/30/2025 |
| Angel Qin, MD | Faculty | Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-Pfizer (Relationship has ended)|Consulting Fee-Janssen|Honoraria-OncLive (Relationship has ended)|Consulting Fee-Regeneron (Relationship has ended)|Consulting Fee-Summit Therapeutics (Relationship has ended)|Consulting Fee-AbbVie|Honoraria-Axiom|Consulting Fee-BMS - 08/04/2025 |
| Ryan D Gentzler, MD | Faculty | Consulting Fee-Boehringer Ingelheim (Relationship has ended)|Consulting Fee-Astrazeneca (Relationship has ended)|Consulting Fee-GlaxoSmithKline (Relationship has ended)|Consulting Fee-AbbVie (Relationship has ended)|Consulting Fee-Daiichi Sankyo (Relationship has ended)|Consulting Fee-Amgen (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-Regeneron (Relationship has ended)|Consulting Fee-Merus (Relationship has ended)|Grant or research support-Eli Lilly|Grant or research support-Prelude Therapeutics|Grant or research support-Tempus|Grant or research support-Nalo Therapeutics|Grant or research support-Puma|Grant or research support-BMS|Grant or research support-Dizal|Grant or research support-Chugai|Grant or research support-Amgen|Grant or research support-Astrazeneca|Grant or research support-Janssen|Grant or research support-Daiichi Sankyo|Grant or research support-Takeda|Grant or research support-Merck - 09/04/2025 |
| Dwight Owen, MD | Faculty | Grant or research support-BMS|Honoraria-Chugai (Relationship has ended)|Grant or research support-Merck|Grant or research support-Pfizer|Grant or research support-Onc.AI|Grant or research support-Palobiofarma|Grant or research support-Genentech|Grant or research support-Astrazeneca - 09/25/2025 |
| Marcia K Horn, JD | Faculty | Nothing to disclose - 08/17/2025 |
| Mara Antonoff, MD | Faculty | Consulting Fee-Astrazeneca|Consulting Fee-BMS (Relationship has ended)|Consulting Fee-johnson and johnson|Consulting Fee-Merck (Relationship has ended) - 09/25/2025 |
| Rafeh Naqash, MD | Faculty |  |
| Julia Rotow, MD | Faculty | Consulting Fee-Amgen (Relationship has ended)|Consulting Fee-Astrazeneca|Grant or research support-Astrazeneca|Consulting Fee-BIoAtla (Relationship has ended)|Consulting Fee-Bristol Myers Squibb|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Daiichi-Sankyo|Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-G1 Therapeutics (Relationship has ended)|Consulting Fee-Guardant Health (Relationship has ended)|Consulting Fee-Johnson and Johnson|Consulting Fee-Jazz (Relationship has ended)|Consulting Fee-Merus (Relationship has ended)|Consulting Fee-Nuvation Bio (Relationship has ended)|Consulting Fee-Pfizer (Relationship has ended)|Consulting Fee-Sanofi-Genzyme (Relationship has ended)|Consulting Fee-Summit|Consulting Fee-Novocure (Relationship has ended)|Consulting Fee-Takeda (Relationship has ended)|Grant or research support-Bicycle Therapeutics|Grant or research support-Altor Biosciences|Grant or research support-BioAtla|Grant or research support-Blossom Hill|Grant or research support-Blueprint Medicines|Grant or research support-Enliven|Grant or research support-EpimAb|Grant or research support-Black Diamond|Grant or research support-LOXO Oncology|Grant or research support-ORIC|Grant or research support-AbbVie|Grant or research support-RedCloud|Grant or research support-Summit|Grant or research support-Synthekine|Grant or research support-Immunity Bio|Grant or research support-Regeneron - 08/29/2025 |
| Jacob Sands, MD | Faculty |  |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 6.00 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part 2: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Please allow a minimum of 3 days to process this request.